Product news from the 09/05/06 News Brief

Share this article:
The FDA granted tentative approval to Mylan Pharmaceuticals’ Abbreviated New Drug Application for Fluoxetine capsules, a generic version of Eli Lilly’s Sarafem and Pulvules capsules, which had annual US sales of approximately $52 million for the 12 months ending June 30, 2006. Fluoxetine Capsules are indicated for the treatment of premenstrual dysphoric disorder (PMDD). They are the AB-rated
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.